Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PCV21 Vaccination in PPSV23-experienced Immunocompromised Veterans
NCT06271681Phase 4Not yet recruiting
- Sponsor
- VA Sierra Nevada Health Care System
- Start
- Jan 2026
- Primary completion
- Jan 2027
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 4, open-label, single-arm trial of PCV21 in pneumococcal disease, sponsored by VA Sierra Nevada Health Care System. Primary endpoint: Change in opsonophagocytic assay (OPA) geometric mean titers (GMT) at 24 months. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
PCV21
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06271681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271681.